Monoclonal antibody · Antagonist of RANKL (TNFSF11) (TNFSF11) · developed by Fresenius Kabi SwissBioSim GmbH
FKS518 is a denosumab biosimilar given subcutaneously by prefilled syringe. It is studied in postmenopausal osteoporosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04934072 | Phase 3 | Postmenopausal Osteoporosis | Completed | FMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Postmenopausal Osteoporosis
Updated Nov 8, 2026. Something wrong or missing? Report it on the FMS page.
See FMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FMS catalysts and pipeline →